Interchangeability of gabapentin generic formulations in the Netherlands: a comparative bioavailability study

Y. Yu, S. Teerenstra, F. Vanmolkot, C.K. Neef, D. Burger, M. Maliepaard

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)

Abstract

To investigate the so-called "drift" with generic-generic drug substitution, a single-dose, four-way crossover comparative bioavailability study was performed involving 24 healthy subjects and three generic and one branded formulation of a tablet containing 800 mg gabapentin as test medication. The results showed that the 90% confidence intervals (CIs) for the area under the drug concentration-time curve (AUC(0-t)) and for the peak drug concentration (C(max)) were within the acceptance range of 80-125% for all comparisons. The safety profiles of the different gabapentin formulations were comparable. To conclude, all three generic formulations of gabapentin were found to be bioequivalent with the branded formulation and with each other, indicating that the formulations are interchangeable. These results strongly indicate the absence of "drift" with gabapentin generic-generic substitution.
Original languageEnglish
Pages (from-to)519-524
JournalClinical Pharmacology & Therapeutics
Volume94
Issue number4
DOIs
Publication statusPublished - 1 Jan 2013

Cite this

Yu, Y. ; Teerenstra, S. ; Vanmolkot, F. ; Neef, C.K. ; Burger, D. ; Maliepaard, M. / Interchangeability of gabapentin generic formulations in the Netherlands: a comparative bioavailability study. In: Clinical Pharmacology & Therapeutics. 2013 ; Vol. 94, No. 4. pp. 519-524.
@article{03d75fc10f364b03b50d2cf7805994be,
title = "Interchangeability of gabapentin generic formulations in the Netherlands: a comparative bioavailability study",
abstract = "To investigate the so-called {"}drift{"} with generic-generic drug substitution, a single-dose, four-way crossover comparative bioavailability study was performed involving 24 healthy subjects and three generic and one branded formulation of a tablet containing 800 mg gabapentin as test medication. The results showed that the 90{\%} confidence intervals (CIs) for the area under the drug concentration-time curve (AUC(0-t)) and for the peak drug concentration (C(max)) were within the acceptance range of 80-125{\%} for all comparisons. The safety profiles of the different gabapentin formulations were comparable. To conclude, all three generic formulations of gabapentin were found to be bioequivalent with the branded formulation and with each other, indicating that the formulations are interchangeable. These results strongly indicate the absence of {"}drift{"} with gabapentin generic-generic substitution.",
author = "Y. Yu and S. Teerenstra and F. Vanmolkot and C.K. Neef and D. Burger and M. Maliepaard",
year = "2013",
month = "1",
day = "1",
doi = "10.1038/clpt.2013.108",
language = "English",
volume = "94",
pages = "519--524",
journal = "Clinical Pharmacology & Therapeutics",
issn = "0009-9236",
publisher = "Wiley",
number = "4",

}

Interchangeability of gabapentin generic formulations in the Netherlands: a comparative bioavailability study. / Yu, Y.; Teerenstra, S.; Vanmolkot, F.; Neef, C.K.; Burger, D.; Maliepaard, M.

In: Clinical Pharmacology & Therapeutics, Vol. 94, No. 4, 01.01.2013, p. 519-524.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Interchangeability of gabapentin generic formulations in the Netherlands: a comparative bioavailability study

AU - Yu, Y.

AU - Teerenstra, S.

AU - Vanmolkot, F.

AU - Neef, C.K.

AU - Burger, D.

AU - Maliepaard, M.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - To investigate the so-called "drift" with generic-generic drug substitution, a single-dose, four-way crossover comparative bioavailability study was performed involving 24 healthy subjects and three generic and one branded formulation of a tablet containing 800 mg gabapentin as test medication. The results showed that the 90% confidence intervals (CIs) for the area under the drug concentration-time curve (AUC(0-t)) and for the peak drug concentration (C(max)) were within the acceptance range of 80-125% for all comparisons. The safety profiles of the different gabapentin formulations were comparable. To conclude, all three generic formulations of gabapentin were found to be bioequivalent with the branded formulation and with each other, indicating that the formulations are interchangeable. These results strongly indicate the absence of "drift" with gabapentin generic-generic substitution.

AB - To investigate the so-called "drift" with generic-generic drug substitution, a single-dose, four-way crossover comparative bioavailability study was performed involving 24 healthy subjects and three generic and one branded formulation of a tablet containing 800 mg gabapentin as test medication. The results showed that the 90% confidence intervals (CIs) for the area under the drug concentration-time curve (AUC(0-t)) and for the peak drug concentration (C(max)) were within the acceptance range of 80-125% for all comparisons. The safety profiles of the different gabapentin formulations were comparable. To conclude, all three generic formulations of gabapentin were found to be bioequivalent with the branded formulation and with each other, indicating that the formulations are interchangeable. These results strongly indicate the absence of "drift" with gabapentin generic-generic substitution.

U2 - 10.1038/clpt.2013.108

DO - 10.1038/clpt.2013.108

M3 - Article

VL - 94

SP - 519

EP - 524

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

SN - 0009-9236

IS - 4

ER -